TherapeuticsMD met with FDA officials one month ago but is still waiting for a resolution to the agency’s rejection of its estrogen therapy for postmenopausal women known as TX-004HR. The “regulatory update” announced Monday with no clear plan forward was not well received by investors. TherapeuticsMD shares are down 11 percent.

TX-004HR is a capsule filled with estradiol (bioidentical estrogen) that menopausal women insert into their vaginas to deal with the bothersome vaginal changes — dryness, itching, pain during sex — that can occur when the body’s own estrogen levels fall.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.